A number of well-known pharmaceutical companies to be listed.

Recently, a number of well-known pharmaceutical companies are seeking to go public or have been successfully listed.
on the whole, the track of drug companies seeking capitalisation is hot.
Ganli Pharmaceuticals, which focuses on the research and development, production and sales of recombinant insulin analogue API and injections, landed on A-shares on June 29. On the first day of the listing
, Gan Li Pharmaceuticals opened at 91.18 yuan per share, up 44% with a market value of 36.572 billion yuan.
public information shows that, as a leading domestic insulin industry, Ganli Pharmaceuticals in the field of biosynthetic insulin product coverage, research and development technology, etc. are in the leading domestic level.
currently has the products of Glycol Pharmaceuticals covering long-acting insulin glargine, quick-acting insulin and sperm protein zinc recombinant insulin mixed injection (25R), Mendong insulin four recombinant insulin similar species, involving long-acting, quick-acting, medium-effect three insulin functional market segments.
at present, the main sources of income of Ganli Pharmaceuticals are "Long Xiuyu" and "Fast Show", of which the recombinant insulin glargine injection (ChangXiuYu) is the most important source of revenue of Ganli Pharmaceuticals, sales revenue accounted for the proportion of the main business revenue in 2017-2019 was 91.51%, 94.74% and 87.91%, respectively.
2017-2019, Ganli Pharmaceuticals had revenues of RMB2,371 million, RMB2,387 million and RMB2,895 million, while net profit for the same period was RMB1,080 million, RMB934 million and RMB1,167 million, respectively.
Chuanning Bio On June 24, Sichuan Collon Pharmaceuticals announced that it intends to spin off its controlling subsidiary, Yili Chuanning Biotechnology Co., Ltd. ("ChuanNing BiologicalS") and list editon on the Shenzhen Stock Exchange GEM.
the spin-off is completed, the equity structure of Collon Pharmaceuticals will not change and will retain control of Kawaning Bio.
public information shows that Koren Pharmaceuticals is mainly engaged in infusion products, non-infusion preparations, antibiotic intermediates research and development, production and sales.
Chuanning Bio is mainly responsible for the development, production and marketing of antibiotic intermediates such as Collone Pharmaceuticals antibiotic intermediates, mainly engaged in the development, production and marketing of antibiotic intermediates such as thiocyanic acid erythromycin, 6-APA, 7-ACA, D-7ACA and penicillin G potassium salts.
according to the announcement, at present, Collum Pharmaceuticals directly and indirectly holds 88.49% of the shares of Kawaning Bio. On May 30,
, Collon Pharmaceuticals announced that it would make a joint-stock transformation of Kawaning Bio, paving the way for the spin-off and listing of Kawaning Bio.
, on June 13, Tianshili Bio announced that Tianshili Pharmaceutical Group intends to spin off its subsidiary Tianshili Biopharmaceutical Co., Ltd. (hereinafter referred to as "Tianshili Bio") to list on the Shanghai Stock Exchange.
public information shows that Tianshi biology's main business is engaged in the development and commercialization of biopharmaceutical products, mainly focusing on cardiovascular and cerebrovascular, tumor and autoimmune, digestive metabolism, the three major in China has a large number of unmet clinical needs of the treatment field.
in addition to Tianshili Biology, Tianshili's main business is in the field of Chinese medicine and chemical medicine research, production preparation and marketing.
after the listing of this spin-off Tianshili Bio, Tianshili will still maintain control over Tianshili Bio, Tianshili Bio remains a subsidiary within the scope of its consolidated statements, it is expected that after the completion of this spin-off, Tianshili Biowill will directly connect to the capital market, can use the new listing platform to support its future business development, and release The value of Tianshi Shishi Biopharmaceutical plate.
First Sound Pharmaceuticals submitted its application for listing to the Hong Kong Stock Exchange on June 10.
public information shows that, in 1995, First Sound Pharmaceuticals, was established in 2007 as China's first bio- and chemical pharmaceutical company on the New York Stock Exchange, raising $226 million with a market value of more than $1 billion;
-first-sound pharmaceuticalindustry focuses on tumor diseases (including cell therapy), central nervous system diseases and autoimmune diseases. In recent years,
, the performance of First Sound Pharmaceuticals has shown a steady upward trend: in 2017-2019, Firstsound Pharmaceuticals achieved revenue of 3.868 billion yuan, 4.514 billion yuan and 5,037 million yuan, respectively, and net profit of 350 million yuan, 730 million yuan and 1.004 billion yuan.
the same period, the company's first-class innovative drug revenue as a percentage of total revenue of 21.4%, 25.5% and 32.9%.
it is understood that the pharmaceutical industry has 5 products for the treatment of cancer diseases, 3 products for the treatment of central nervous system diseases, 4 products for the treatment of autoimmune diseases, 3 products for the treatment of cardiovascular diseases, 15 products used to treat infectious diseases caused by bacteria or viruses, and a variety of products for the treatment of other diseases.
Legendary Creatures On June 5, Kingsbury Biotech's spin-off subsidiary, Nanjing Legendary Biotech Co., Ltd. ("LegendS" LEGN), was listed on NASDAQ with a price of $23 per share.
it is understood that Legendary Bio's IPO is the largest in the US biotech sector so far in the year of 2020.
public information shows that Kingsley Biotech was established in 2002 and listed on the Main Board of the Hong Kong Stock Exchange in 2015.
enterprises have leading gene synthesis technology, covering life science services and products, industrial synthetic biological products, biopharmaceutical CDMO and cell therapy four areas. Founded in 2014,
Legendary Bio, a clinical biopharmaceutical company dedicated to the discovery and development of new cell therapy for blood/tumors, infectious diseases and autoimmune diseases.
2017 and 2018, Legendary Bio has attracted widespread attention in the industry with its breakthrough in CAR-T, and in 2018 it won the first clinical trial approval for CAR-T cell therapy in China.
it is understood that Legendary Bio will remain a subsidiary of Kingsley Holdings after the listing, with Kingsley Biotech holding more than 66 per cent of the company.
Hundred-gram biology On May 25, Changchun Gaoxin, a leading domestic human growth hormone company, announced plans to spin off its subsidiary, Changchun Baxter Biotech Co., Ltd. ("Baike Bio") to list.
public information shows that Changchun High-tech's main business for biopharmaceuticals and traditional Chinese medicine research and development, production and sales, supplemented by real estate development, property management and real estate leasing business.
its pharmaceutical products cover genetic engineering drugs, bio-vaccines, modern Chinese medicine and other medical sub-fields, is the main source of performance.
the main business of 100 grams of biological for human biological vaccine research and development, production, sales, the main products for chickenpox vaccine, human rabies vaccine, nasal spray influenza vaccine.
according to the announcement, Changchun Gaoxin currently directly holds 46.15% of the shares of Bacek Bio, is the largest shareholder of Bacquenby-old Bio.
On May 11, Fosun Pharma announced that the China Securities Regulatory Commission's International Cooperation Department had no objection to the company's previous overseas listing of Gland Pharma.
the company said it expects Togo Pharma to remain a controlling subsidiary of the company after its overseas listing is completed.
public information, Gland Pharma was founded in 1978, mainly engaged in the development and production of small molecule injection genericdrugs, is the first in India to obtain FDA approval of the u.S. injection drug manufacturing enterprises, and access to the global regulatory market GMP certification, its business revenue mainly from the United States and Europe.
as of November 2, 2019, Fosun Pharma (through a controlling subsidiary) holds a total 74% stake in Gland Pharma.
before that, Fosun Pharma had successfully separated its subsidiary FuHong Hanxuan and listed it.
September 25, 2019, Fu Hong Hanxuan officially landed on the Hong Kong Stock Exchange.
hundred Otai landing four months after the company board, Bai Otai began to prepare for the listing of Hong Kong stocks. on June 17,
, bai-Aotai announced that the company's board of directors had considered and considered a motion to approve its public offering of foreign-traded foreign shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange.
public information shows that BaiotaI Biopharmaceutical Co., Ltd. was founded in 2003, is an innovative biopharmaceutical company with innovative drugs and biosimilars research and development as the core, products for the treatment of tumors, autoimmune diseases, cardiovascular diseases and other major diseases endangering human life or health. On February 21,
, Bai Otai officially listed on the company board, with a price of 32.76 yuan.
as of the close on June 22, the share price was 56.98 yuan per share, with a total market value of 23.59 billion yuan.
has been in a loss-making state since Baiaotai has not been listed for sale before, so it has been in a loss-making state - the 2019 annual report shows that in 2017-2019, Bai-Aotai realized operating income of 200.89 million yuan, 0 yuan, 700,000 yuan, respectively;
but with the first product, Adamu monoantithem biosimilars, was approved for sale, Baxter also gained some revenue.
in addition to Adamu monoto-resistance, Baiathai also has a number of research products, as of December 31, 2019, the company has 1 product has been approved for market, there are 20 major in research products, of which 1 product has submitted ndA application, 3 products in Phase III clinical research stage, 1 product in Phase II clinical research stage, 4 products in the phase II clinical research stage, the company has a number of innovative antibodies in the clinical research phase.
Jiahe Bio recently, the sing-anti-drug research and development company Jiahe Bio submitted a listing application to the Hong Kong Stock Exchange, Goldman Sachs, JPMorgan Chase and Jeffery as co-sponsors of the listing.
Jiahe Bio's predecessor is Xinrun (Shanghai) Biopharmaceutical Co., Ltd., founded in 2007, the earliest investor is the foreign-backed Huisheng Group.
focuses on the development and commercialization of oncology and autoimmune drugs, covering five of the world's top 10 best-selling drugs.
public information shows that Jiahe Bio focuses on key therapeutic areas to address a large number of unmet medical needs in tumors, autoimmune and other chronic diseases.
Jiahe Bio has not yet been approved for commercial sales, with total losses of RMB288 million and RMB523 million for the year ended December 31, 2018 and December 31, 2019, respectively.
company's operating losses are largely derived from research and development expenses, administrative expenses and financing costs.
in the pre-listing shareholder structure of Jiahe Bio, HHJH and HM Healthcare, owned by GaoYu Capital, hold a total of 35.59 per cent, making them the majority shareholders in the company.
in addition to Gao's capital, Kang's subsidiary Kangjia Medical and Healthcare have a combined stake of 16.07 percent, making it the second largest shareholder, with Kang and Medical holdings at 12.32 percent and Kangjia Medical holdings at 3.75 percent.
Jiahe Bio is expected to raise HK$2.48 billion in the listing.
, HK$372 million was spent on the allocation of GB491 for planned clinical trials and registration preparation, and HK$1.24 billion for the allocation of ongoing and planned clinical trials, indications expansion, registration and filing preparation and potential commercialization of core products.
analysis pointed out that the beginning of the new crown epidemic once again witnessed the potential of Chinese pharmaceutical enterprises, in the future, the hope of greater development, pharmaceutical enterprises are more popular with the capital market.
.